ArticleBiomaterials research2025
Facile Synthesis of Designer Shape-Defined Mesoporous Metal Nanoenzymes as Therapeutics for Diseases Involving Excessive Oxidative Stress.
Article in Biomaterials research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Nanomaterials-Based Immunotherapy for Atherosclerosis.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mesoporous metal nanomaterials (MMNs) have gained interest in biomedicine for their unique properties, but their potential is limited by the predominance of spherical shapes and the neglect of morphological effects on biological activity, which hinders the reasonable evaluation of morphology-dependent enzyme-like activities and biological behaviors and its further biomedical applications. It is therefore imperative to find an effective and facile method to design and prepare MMNs with novel, well-defined morphologies. Herein, we fabricated 3 mesoporous platinum nanoenzymes including sphere, rod, and bipyramid topologies [Au@mesoPt sphere, Au@mesoPt rod, and Au@mesoPt bipyramid nanoparticles (NPs), respectively] via a facile atomic layer deposition method using gold NPs (Au NPs) as the templated cores and Pluronic F127 as a structure-directing agent. The obtained Au@mesoPt NPs could enhance cellular uptake efficiency and prolong blood elimination half-lives, which helped more cancer cell spheroid permeation and accumulation at the disease sites post-injection. Au@mesoPt NPs could obviously alleviate atherosclerosis through reactive oxide species (ROS) scavenge due to its catalase-like activity and inhibition of pro-inflammatory cytokine release. Due to the role of metal nanoenzymes containing high-order-number (
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.